Olmesartan MedoxomilALKEM OLMESARTAN
Recommended CardiovascularUnrestrictedFirst-line line
Treatment of hypertension. Olmesartan medoxomil is an angiotensin II antagonist for the management of essential hypertension.
2
Submissions
2005–05
On the record
—
ICER range
Cost-min
Cost basis
Access path
- TGA registered · ALKEM OLMESARTAN
TGA label equal than the PBS population
- Nov 2005Recommended
Evidence: RCT | Single-arm | Registry | Cost-minimisation → RCT
- Nov 2005Recommended
Evidence: RCT | Single-arm | Registry | Cost-minimisation → RCT
- PBS listing · Unrestricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated by design
The choice of the cost-minimisation approach was considered valid by the PBAC. PBAC · 2005
Cost-effectiveness accepted
Decision context
PopulationPatients with essential hypertension; head-to-head trial included patients with mild-to-moderate hypertension receiving olmesartan 20 mg or irbesartan 150 mg for 8 weeks
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2005 | Recommended | irbesartan | — | RCT | Single-arm | Registry | Cost-minimisation · DBP, SBP |
| Nov 2005 | Recommended | irbesartan | — | RCT · DBP |
Similar precedents
Losartan79%Olmesartan Medoxomil With Hydrochlorothiazide79%Olmesartan Medoxomil With Amlodipine76%Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide73%Amlodipine Besylate With Valsartan66%Valsartan With Hydrochlorothiazide65%Telmisartan With Amlodipine64%Amlodipine (As Besylate) With Valsartan And Hydrochlorothiazide63%
Regulatory · TGA
Label equal than PBS population — Both texts describe treatment of hypertension in adults with no additional restrictions or population subsets specified.